Organogenesis (ORGO)
(Delayed Data from NSDQ)
$3.25 USD
+0.05 (1.56%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.25 0.00 (0.00%) 7:08 PM ET
2-Buy of 5 2
A Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.25 USD
+0.05 (1.56%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.25 0.00 (0.00%) 7:08 PM ET
2-Buy of 5 2
A Value D Growth B Momentum B VGM
Zacks News
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 50.00% and 1.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Organogenesis (ORGO) closed the most recent trading day at $11.44, moving +0.53% from the previous trading session.
Analysts Estimate Organogenesis (ORGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
On Organogenesis' (ORGO) upcoming third-quarter earnings call, investor focus is likely to be on the sales performance of its two segments - advanced wound care, and surgical & sports medicine.
Organogenesis (ORGO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Organogenesis (ORGO) closed the most recent trading day at $10.98, moving +0.64% from the previous trading session.
Zacks.com featured highlights include: SunOpta, Citi Trends, Organogenesis, Tapestry and Venus Concept
by Zacks Equity Research
Zacks.com featured highlights include: SunOpta, Citi Trends, Organogenesis, Tapestry and Venus Concept
Forget Bargains, Play 5 Stocks with Rising P/E Instead
by Sanghamitra Saha
Forget undervalued stocks, there is room for upside even in stocks with rising P/E.
Can Organogenesis (ORGO) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Organogenesis (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Organogenesis (ORGO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 114.29% and 16.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in the second quarter of 2021. However, with demand trends expected to improve, XNCR, ORGO, CPIX, and ACER may prove to be good additions to one's portfolio.
Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review
by Zacks Equity Research
Amryt (AMYT) is seeking approval for Oleogel-S10 as a potential treatment for patients with rare and distressing genetic skin disorder, epidermolysis bullosa.
Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed
by Zacks Equity Research
Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.
Organogenesis (ORGO) Stock Jumps 7.7%: Will It Continue to Soar?
by Zacks Equity Research
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 275.00% and 18.83%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis Holdings' (ORGO) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Organogenesis Holdings (ORGO).
Organogenesis (ORGO) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 25.00% and 1.43%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in 2021. However, with demand trends expected to improve, USNA, RDUS, ONCT, ORGO and TPTX may prove to be good additions to one's portfolio.
Organogenesis Holdings' (ORGO) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Organogenesis Holdings (ORGO).
Aurinia (AUPH) Gets FDA Nod for Kidney Disorder Drug Lupkynis
by Zacks Equity Research
Aurinia (AUPH) gets approval from the FDA for Lupkynis as a treatment for active lupus nephritis, a disease that causes irreversible kidney damage.
Earnings Estimates Rising for ORGANOGENESIS (ORGO): Will It Gain?
by Zacks Equity Research
ORGANOGENESIS (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.